• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Ilumya (tildrakizumab-asmn)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Ilumya (tildrakizumab-asmn)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Ilumya (tildrakizumab-asmn) is an interleukin-23 antagonist. 

    Ilumya is specifically indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

    Ilumya is supplied as a solution for subcutaneous injection. The recommended dose is 100 mg at Weeks 0, 4, and every twelve weeks thereafter. 

    Clinical Results

    FDA Approval

    The FDA approval of Ilumya for the treatment of adults with moderate-to-severe plaque psoriasis was based on data from the pivotal Phase III reSURFACE clinical development program. In the two multicenter, randomized, double-blind, placebo-controlled trials (reSURFACE 1 and reSURFACE 2), 926 adult patients were treated with Ilumya (N=616) or placebo (N=310). Both studies met the primary efficacy endpoints, demonstrating significant clinical improvement with Ilumya 100 mg compared to placebo when measured by at least 75 percent of skin clearance (Psoriasis Area Sensitivity Index or PASI 75) and Physician's Global Assessment (PGA) score of "clear" or "minimal" at week 12 after two doses. Of the patients in the reSURFACE 1 study 74% (n=229) achieved 75 percent skin clearance at week 28 after three doses, and 84 % of patients who continued receiving Ilumya 100 mg maintained PASI 75 at week 64 compared to 22 % of patients who were re-randomized to placebo. In addition, 69% of the patients receiving Ilumya 100 mg who had a PGA score of "clear" or "minimal" at week 28 maintained this response at week 64 compared to 14% of patients who were re-randomized to placebo.

    Side Effects

    Adverse effects associated with the use of Ilumya may include, but are not limited to, the following:

    • upper respiratory infections
    • injection site reactions
    • diarrhea

    Mechanism of Action

    Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.

    Additional Information

    For additional information regarding Ilumya or plaque psoriasis, please visit http://www.sunpharma.com/

    Approval Date: 2018-03-01
    Company Name: Sun Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Qualification-360x240.png

      Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

    • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

    • MachineLearning-360x240.png

      Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

    • VirtualTraining-360x240.png

      Virtual Training Evolves into More In-Depth Learning, Improved Communications

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing